CD4 and COVID-19: recently demonstrated that using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2-specific CD8+ and CD4+ T cells were identified in ~ 70% and 100% of COVID-19 convalescent patients, respectively14.